Ryoncil is part of a development programme for inflammatory diseases such as SR-aGvHD in adults, and biologic-res ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...

Mesoblast's remestemcel (Ryoncil) is FDA-approved for steroid-refractory acute graft-versus-host disease in patients two months and older, marking a significant milestone for MSC therapies in the US.

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...

Top 2024 performers include multiple health care stocks with unique catalysts, as well as several quantum computing ...

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

New data shows the 40 key ASX biotechs gained an average 50% in 2024 - but not all of them joined the winner's circle.

Mesoblast Limited (AU:MSB) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older: Melbourne, Australia Monday, December 23, 2024 ...

The ORR was 70% in patients treated with remestemcel-L, with 30% having a complete response and 41% having a partial response. The Food and Drug Administration (FDA) has approved Ryoncil ...